Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Reset all filters
01 16Adempas
02 3Alliance revenue - Adempas/Verquvo
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 760
2019 Revenue in Millions : 506
Growth (%) : 50
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 813
2020 Revenue in Millions : 760
Growth (%) : 18
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 685
2021 Revenue in Millions : 813
Growth (%) : -16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 716
2022 Revenue in Millions : 685
Growth (%) : 1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 759
2023 Revenue in Millions : 716
Growth (%) : 6
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 366
2016 Revenue in Millions : 315
Growth (%) : 16
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 402
2017 Revenue in Millions : 333
Growth (%) : 21%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 456
2018 Revenue in Millions : 388
Growth (%) : 17
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 501
2019 Revenue in Millions : 419
Growth (%) : 20

Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 252
2020 Revenue in Millions : 220
Growth (%) : 15




